Table I. Demographic Characteristics of RRMS Patients.
| Untreated (n=18) | DMF 4-6M (n=20) | DMF 18-26M (n=18) | P | Longitudinal Cohort (n=9) | |
|---|---|---|---|---|---|
| Age (year) 1 | 43 ± 8 | 43 ± 8 | 46 ± 9 | 0.601 | 45.7 ± 8.8 |
| Gender2 | |||||
| Female | 15 | 16 | 14 | 0.915 | 7 |
| Male | 3 | 4 | 4 | 2 | |
| Race2 | 1.000 | ||||
| Caucasian | 17 | 19 | 17 | 8 | |
| African American | 1 | 1 | 1 | 1 | |
| Disease duration (year) 3 | 0.7(0.1,3.9) | 1.1(0.5,6.2) | 2.6(2.2,6.9) | 0.738 | 0.7(0.1,5.3) |
| Baseline EDSS1 | 2.4 ± 1.6 | 2.1 ± 1.2 | 2.1 ± 1.3 | 0.782 | 2.5 ± 1.8 |
| Treatment2,4 (Tx) Naive | 8 (44.5%) | 9(45%) | 9 (50%) | 0.828 | 3 (33.3%) |
| Prior Tx5 (> 6 month): | 5(27.8%) Avonex (2), Copaxone(2), Rebif, | 4(20%) Avonex, Copaxone(2), Rebif | 2(11.1%) Avonex, Etanercept6 | 1 (11.1%) Avonex | |
| Prior Tx5 (3-6 month) | 1(5.5%) Avonex | 1(5%) Avonex, | 2(11.1%) Avonex, Tysabri | 1 (11.1%) Avonex | |
| Prior Tx5 (< 3 month) | 4(22.2%) Tysabri, Betaseron, Rebif, Copaxone | 6(30%) Avonex, Betaseron, Copaxone(2), Rebif,Tysabri | 5(27.8%) Avonex, Betaseron, Copaxone, Rebif, Tysabri | 4(44.4%) Avonex, Betaseron, Rebif, Tysabri | |
1
Data presented as mean ± SD; p-value was from ANOVA test
2
Data presented as number (%); p-value was from Chi-square or Fisher exact test
3
Data presented as median (Q1, Q3); p-value was from Kruskal–Wallis ANOVA test
4
Disease modifying therapy prior to baseline draw
5
Treatment prior to baseline draw, not time point
6
Prior treatment for Ankylosing Spondilitis